Protara Therapeutics reports Q3 EPS (50c), consensus (52c)

“We continue to make significant progress advancing all of our ongoing programs as we strive toward our goal of bringing life-changing therapies to patients impacted by cancer and rare diseases,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics (TARA). “Notably, we remain on track to report interim data in the fourth quarter of 2024 from our ADVANCED-2 study of TARA-002 in patients with non-muscle invasive bladder cancer. Given its ease of use, favorable safety profile, and encouraging early clinical data, we believe TARA-002 could be an impactful addition to the NMIBC treatment landscape. In addition to our NMIBC program, we remain on track to commence the pivotal THRIVE-3 study of intravenous Choline Chloride, for which we recently received Fast Track designation from the U.S. Food and Drug Administration, in the first quarter of 2025. Finally, we continue to expect interim data in the first half of 2025 from our ongoing Phase 2 STARBORN-1 trial of TARA-002 in lymphatic malformations, a rare condition primarily impacting children for which there are no FDA approved therapies.”